Myriad Genetics, Inc. (MYGN) Covered Calls

Myriad Genetics, Inc. covered calls Myriad Genetics, Inc. is a healthcare company, focused on the development and marketing of novel molecular diagnostic products.

You can sell covered calls on Myriad Genetics, Inc. to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for MYGN (prices last updated Mon 4:16 PM ET):

Myriad Genetics, Inc. (MYGN) Stock Quote
Last Change Bid Ask Volume P/E Market Cap
15.22 -0.03 14.30 16.15 1.2M - 1.4
Covered Calls For Myriad Genetics, Inc. (MYGN)
Expiration Strike Call Bid Net Debit Return
If Flat
Annualized
Return If Flat
Dec 20 15 0.00 16.15 -7.1% -78.5%
Jan 17 15 0.55 15.60 -3.8% -22.7%
Subscribers get access to the full covered call chain, and more features.

Want to make money with covered calls?  Sign Up For A Free Trial


Extended Business Description

Myriad Genetics, Inc. is a molecular diagnostic company, which focuses on developing and marketing novel predictive and personalized medicines and prognostic medicine tests. It operates through the following segments: Research, Molecular Diagnostics and Companion Diagnostics. The Research segment focuses on the discovery of genes related to major common diseases and includes corporate services such as finance, human resources, legal and information technology. The Molecular Diagnostics segment provides testing that is designed to assess an individual's risk for developing disease later in life, identify a patient's likelihood of responding to drug therapy and guide a patient's dosing to ensure optimal treatment, or assess a patient's risk of disease progression and disease recurrence. The Companion Diagnostics segment provides testing products and services to the pharmaceutical, biotechnology and medical research industries. The company was founded by Walter A. Gilbert, Mark H. Skolnick and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake, UT.